The protocol at a glance
In the phase 2 trial, adults injected eloralintide once a week under the skin for 48 weeks. Some groups stayed on one fixed amount. Two groups stepped up to 9 mg.
| Phase 2 group | Weekly amount (48 weeks in total) |
|---|---|
| Fixed | 1 mg, 3 mg, 6 mg or 9 mg the whole time |
| Step-up A | 6 mg for 20 weeks, then 9 mg for 28 weeks |
| Step-up B | 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks |
| Route | Injection under the skin, once a week |
From the registry entry for NCT06230523 and the Lancet paper (Billings et al. 2025). This is a trial schedule, not a label. No dosing label exists yet.
Community protocols often talk about starting very low (around 500 mcg) and building up slowly. This is community talk, not a trial schedule.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing calculator
Enter the vial size, the water you add and the amount you want to draw; it gives the mark on a 100-unit (1 mL) insulin syringe.
What the trials found
Phase 2 trial, 263 adults with obesity or overweight, no diabetes, 48 weeks. Average change in body weight (efficacy estimand, which counts the effect when treatment is taken as planned):
Billings LK et al. Lancet 2025 (DOI 10.1016/S0140-6736(25)02155-5); posted results at ClinicalTrials.gov NCT06230523. 1 mg gave -9.4%; the two step-up plans gave -19.9% (6 to 9 mg) and -16.5% (3, 6, then 9 mg).
Side effects
- The most common side effects were nausea and tiredness. Nausea reached 64% on 6 mg and 33% on 9 mg, versus 14% on placebo.
- Tiredness reached 43% on 9 mg and 46% on 6 to 9 mg, versus 12% on placebo.
- The step-up 3, 6, 9 mg plan had less nausea (25%) than the 6 mg fixed group. The authors called it generally well tolerated. The trial lasted one year, so long-term safety is unknown.
How it works
Amylin receptor
Amylin is a hormone that helps you feel full. Eloralintide is built to switch on the same receptor, and it only targets that receptor.
Sources
- Billings LK et al. Lancet 2025, 48-week phase 2 trial of eloralintide, NCT06230523 (abstract on PubMed 41207310)
- ClinicalTrials.gov NCT06230523 (arms and posted results)
- ClinicalTrials.gov NCT07321886 and NCT07392190 (phase 3 obesity trials, recruiting)
- Review: Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026